American Well Corp vs Novartis AG — how do they compare? American Well Corp trades at $12.95 (market cap $220.94M), while Novartis AG trades at $152.76 (market cap $295.37B). The key difference: Novartis AG is far larger — about 1336.9× American Well Corp's market cap, and Novartis AG pays a 3.07% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | NVS | |
|---|---|---|
Market Cap | $220.94M | $295.37B |
Sector | Health | Health |
52-Week High | $13.58 | $168.62 |
52-Week Low | $3.78 | $119.31 |
Enterprise Value | $27.98M | $336.69B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $13.58, up 0.44% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses. Recent news includes a key executive joining Amazon's healthcare unit, potentially opening partnership opportunities.
The outlook is cautiously optimistic as AMWL progresses toward cash-flow breakeven, but persistent net losses and negative margins pose risks. Analyst consensus is mixed, with 33% buy ratings, reflecting uncertainty around profitability timelines amid competitive pressures.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →